Osemitamab

CAT: 0804-HY-P9991-01Size: 1 mgDry Ice: YesHazardous: No
CAT#:0804-HY-P9991-01Size:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI) . Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study[1][2].
CAS Number
[2460539-61-9]
Product Name Alternative
TST001
UNSPSC
12352203
Target
Gap Junction Protein
Type
Inhibitory Antibodies
Related Pathways
Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/osemitamab.html
Purity
99.43
Solubility
10 mM in DMSO|H2O
Smiles
[Osemitamab]
Molecular Weight
(146.5 kDa)
References & Citations
[1]Shen L, et al. Osemitamab in combination with capecitabine and oxaliplatin (CAPOX) as a first line treatment of advanced G/GEJ cancer: Updated data of cohort C from a phase I/IIa, multi-center study (TranStar102/TST001-1002) [J]. 2023.|[2]Park Soon Jae, et al. Pharmaceutical composition comprising human hyaluronidase PH20 variants for drug delivery system via subcutaneous injection. World Intellectual Property Organization, WO2023075506 A1. 2023-05-04.|[3]X. Qian, et al., 1560P Osemitamab (TST001) : An ADCC enhanced humanized anti-CLDN18.2 mab, demonstrated improved efficacy in combination with anti-PD-L1/PD-1 mab and oxaliplatin/5-FU in preclinical tumor models. Annals of Oncology, 34 (2), S873, 2023.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2

Popular Products